Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: Clinical presentation, diagnosis, management and emerging therapies by Halatchev, Ilia G et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
3-1-2018 
Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), 
previously known as senile cardiac amyloidosis: Clinical 
presentation, diagnosis, management and emerging therapies 
Ilia G. Halatchev 
Jingsheng Zheng 
Jiafu Ou 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(3):2034-2045jtd.amegroups.com
Clinical case 
A 72-year-old male who presented with progressive dyspnea 
on exertion down to 100 feet. His prior cardiac history 
includes severe aortic stenosis for which he underwent 
bovine bioprosthetic aortic valve replacement. He also 
had a bypass graft with left internal mammillary artery to 
left anterior descending artery at the time of aortic valve 
replacement. Patient further had atrial fibrillation and 
flutter for which he underwent direct current cardioversion. 
His other chronic condition has been hypertension (HTN) 
for which he was on β-blockers and angiotensin converting 
enzyme inhibitors (ACE-i) but had worsening fatigue, 
dyspnea and low blood pressures of 100/60 requiring 
cessation of their use. Of note, patient also has been treated 
for peripheral neuropathy, of unknown etiology, with diffuse 
peripheral neuropathic pain and left focal ulnar neuropathy 
(at the elbow) as well as left carpal tunnel syndrome. 
Based on the patient’s clinical presentation and 
prior cardiac history, he was initially evaluated by 
electrocardiogram (EKG) which showed normal sinus 
rhythm with first degree atrioventricular (AV) block, 
right bundle branch block, and poor R-wave progression. 
A pharmacological stress test (exercise treadmill was 
attempted but patient became dyspneic after 20 seconds) 
with myocardial perfusion imaging showed normal 
myocardial perfusion with no evidence of stress induced 
ischemia. An echocardiography (Echo) showing normal 
left ventricular (LV) size with moderate hypertrophy, low 
normal systolic function and grade III diastolic dysfunction 
as well as apical sparing by longitudinal strain mapping 
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(Figure 1) and normal functioning bioprosthetic aortic 
valve. Brain natriuretic peptide was not obtained at that 
time as patient did not appear volume overloaded on 
exam and by Echo. Based on the clinical presentation of 
β-blockers/ACE-i intolerance and peripheral neuropathies as 
well as normal stress test and Echo findings of moderate 
hypertrophy, grade III diastolic dysfunction and apical 
sparing by longitudinal strain mapping pattern it was 
suspected that patient may have infiltrative cardiac 
process contributing to his condition. This was further 
evaluated by cardiovascular magnetic resonance (CMR) 
showing diffuse subendocardial infiltration by gadolinium 
(Figure 2) and marked increase in T1 relaxation, which has 
consistent with likely infiltrative process such as cardiac 
amyloidosis. After discussion with patient, he wanted to 
proceed with endomyocardial biopsy (EMB) which showed 
positive Congo red staining with apple-green birefringence 
under polarized light (Figure 3) and mass spectroscopy 
analysis of deposited endocardial amyloid fibrils showing 
transthyretin with normal amino acid sequence. The final 
diagnosis was most consistent with wild-type transthyretin 
cardiac amyloidosis (ATTRwt-CA). After the diagnosis of 
ATTRwt-CA, the patient was offered to be evaluated for 
participation in several of the ongoing clinical trials, testing 
novel therapies for cardiac amyloidosis, but he declined. 
The patient has been treated with conservative management 
for the past few years, focused on symptomatic control.
Introduction and epidemiology
The incidence and prevalence of congestive heart failure 
























Figure 1 Longitudinal echocardiography strain depicted in 
bull’s-eye map showing preserved apical strain with reduction of 
mid and basal strain that results in hallmark “cherry on the top” 
pattern, a characteristic strain finding for cardiac amyloidosis.
Figure 2 Characteristic late gadolinium enhancement with phase-
sensitive inversion recovery sequence shows diffuse subendocardial 
enhancement that is evenly distributed throughout the left 
ventricular wall.
Figure 3 Polarized light histologic slide, at 400× magnification, 
showing apple-green birefringence in areas of Congo red stain 
bound to transthyretin amyloid deposit in the extracellular matrix 
of the myocardium. Of note, this should be distinguished from the 
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aging population (1). In US, it affected 5.7 million adults in 
2016 (2), 16 million in EU in 2016 (http://www.ehnheart.
org) and 4.2 million in China in 2011 (publication still 
pending from the China Heart Failure Registry Study 
in 2015) (3). There are three types of CHF: (I) LV ejection 
fraction (LVEF) of less than 40%, called heart failure with 
reduced EF (HFrEF); (II) LVEF of 40–50%, called heart 
failure with mid-range EF (HFmrEF); and (III) LVEF 
greater than 50% called heart failure with preserved 
EF (HFpEF). The epidemiology, pathophysiology and 
outcomes of HFmrEF are poorly understood due to limited 
studies. While, HFrEF has higher incidence and prevalence 
in males (4), with more than 60% caused by coronary 
artery disease (5), HFpEF is more common in women with 
incidence that increases with aging resulting in higher 
prevalence in older adults (4). The pathophysiologies of 
HFpEF are poorly understood and are likely to be due 
to numerous factors resulting in a heterogeneous patient 
population. It is possible that due to the heterogeneity in 
patient population and conditions contributing to HFpEF 
there have been numerous negative clinical trials aimed at 
potential treatment strategies (6).
Cardiac involvement of systemic amyloidosis is one of 
the causes of HFpEF. Systemic amyloidosis is thought to be 
a rare group of diseases, as it is likely underdiagnosed, and is 
characterized by progressive tissue infiltration of insoluble 
fibrillar proteins resulting in extracellular architecture 
disruption that causes organ dysfunction. There are three 
main types of systemic amyloidosis that are known to cause 
cardiac dysfunction and are identified by the amyloid fibril 
protein deposited in the heart, namely; (I) immunoglobulin 
l ight  cha in  (AL)  amyloidos i s ,  ( I I )  ATTRwt-CA, 
previously known as senile cardiac amyloidosis; and (III) 
a mutated ATTR causing hereditary cardiac amyloidosis 
(ATTRm-CA). AL amyloidosis is  most commonly 
diagnosed amyloidosis due to the dysfunction it causes to 
organs, other than the heart, by the amyloid light chain 
deposition. The diagnosis of ATTRm and ATTRwt cardiac 
amyloidosis is more elusive as the clinical presentation 
and severity of organ dysfunction is gradual and variable. 
Studies have shown that 10–25% of patients with HFpEF 
have LV ATTRwt deposition at the time of autopsy (7-9). 
In this review, our aim was to summarize the main 
pathophysiologic changes caused by ATTRwt amyloidosis, 
their clinical presentation and diagnostic evaluation. 
The early identification and diagnosis of this condition 
can result in better current symptomatic management 
and identification of novel emerging therapies aimed at 
altering the progression and hopefully the prognosis of this 
condition. 
Pathophysiology and clinical features
ATTRwt-CA is likely significantly underdiagnosed. 
Although it thought to affect 10–25% of patients with 
HFpEF, suggesting a high prevalence in the elderly 
population, there are less than 100 cases annually at the 
National Amyloidosis Center in UK (10) resulting in 
limited understanding of the natural history of the disease 
due to small patient cohorts. The reason for the low 
diagnostic rate is likely due to the nature of the disease 
pathophysiology that results in a subtle clinical presentation 
in an elderly population who also has frequent comorbid 
conditions and the belief that diagnosis will not affect the 
patients’ outcomes. 
In contrast to other forms of amyloidosis, ATTRwt-CA 
almost exclusively causes clinically evident pathophysiology 
to the heart and the peripheral nerves as well as non-
clinically relevant deposits in the liver and lungs. The 
cardiac manifestations of amyloid wild-type amyloid 
proteins deposition are LV hypertrophy (LVH) with 
increased filling pressure and the “typical” HFpEF with 
symptoms of breathlessness, reduced exercise tolerance, 
fatigue, lower extremities/abdominal swelling, early satiety 
and erectile dysfunction. However, the constellation of 
these cardiac signs and symptoms are very similar to other 
conditions affecting the ATTRwt-CA patient population 
of mostly males who are often greater than 65 years of 
age (11), such as HTN, coronary artery disease, aortic 
stenosis, diabetes, arrhythmias, obstructive sleep apnea and/
or obesity. Hypertrophic cardiomyopathy or hypertensive 
heart disease are also close mimickers of ATTRwt-CA 
clinically and by traditional Echo imaging findings, leading 
to frequent misdiagnosis (12). Additionally, patients at that 
age group often have concomitant monoclonal gammopathy 
of undetermined significance (MGUS) (13) and the 
extracardiac ATTRwt deposition results in bilateral carpal 
tunnel syndrome (14) that precedes cardiac manifestations 
leading to evaluations by non-cardiovascular specialists and 
delay from definitive diagnosis. 
High index of suspicion is necessary for the timely 
diagnosis and treatment of ATTRwt-CA. The key factors 
that may help increase the sensitivity for diagnosis 
of ATTRwt-CA are: LVH without presence of prior 
history of severe or uncontrolled HTN, new onset of 
hypotension, inability to tolerate ACE-i or β-blockers, atrial 
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arrhythmias (15,16), AV nodal dysfunction (13) requiring 
permanent pacemakers and the presence of bilateral carpel 
tunnel syndromes (14) and/or spinal stenosis. Right heart 
failure symptoms are also associated with ATTRwt-CA 
with persistently elevated internal jugular veins, hepatic 
congestion, ascites, abdominal bloating with early satiety 
and chronic lower extremity edema. 
Diagnosis
The definitive diagnosis of ATTRwt-CA is made by 
histology of cardiac biopsy and subsequent genotyping. 
However, EMB is an invasive procedure with associated 
potential risks and is not readily available in many centers. 
There are several non-invasive testing modalities that 
have variable sensitivities and specificities for the diagnosis 
of ATTRwt-CA, including EKG, biomarkers, Echo, 
scintigraphy, CMR, as well as liver and fat pat biopsies that 
should be discussed.
EKG 
EKG is one of the oldest, best described and most widely 
used cardiac diagnostic modalities worldwide. However, 
its use as diagnostic tool for ATTRwt-CA has likely lead 
to falsely reduced clinical suspicion and its underdiagnoses 
of the disease. This is largely from the “classical” teaching 
which dictates that cardiac amyloidosis is associated with 
low voltage (defined as ≤5 mV amplitude in the limb leads 
or ≤10 mV amplitude in the precordial leads) despite the 
presence of LVH and comes from studies of AL amyloid 
(16,17). In recent ATTRwt-CA studies, low voltage has 
been found to have poor independent sensitivity (~30%) for 
its diagnosis (18,19). 
There are numerous other EKG findings that are seen 
in patients with ATTRwt-CA but have low sensitivity and 
specificity for the disease because they are also common 
in age and comorbidities matched patient cohorts: (I) 
38–63% have pseudoinfarct pattern (17,19); (II) 34% 
have poor R-wave progression (19); (III) 16–80% have 
atrial fibrillation (15,18); (IV) 21% have first degree AV 
block (20); and (V) 16% have nonspecific ST-T-wave 
abnormalities (20). Left bundle branch block can be 
potentially useful to differentiate ATTRwt-CA and AL-CA 
as it occurs in 40% vs. 4%, respectively (14). 
Voltage-to-mass ratio, calculated by sum of S wave 
in lead V1 plus R wave in lead V5 or V6 (SV1 + RV5 
or V6) divided by the echocardiographic muscle cross-
sectional area (21), has been shown to have high sensitivity 
and specificity for ATTRwt-CA (14) as compared to 
ATTRm-CA, AL-CA and other age related cardiac 
conditions. Additionally, patients with HTN or LVH 
usually have normal or increased EKG voltage while 
patients with tamponade, pericardial effusion or emphysema 
usually have low EKG voltages with normal LV mass (21).
Echo 
Echo is the most frequently used noninvasive imaging 
test for evaluation of suspected cardiomyopathies, 
like ATTRwt-CA, as it provides both structural and 
functional information with minimal risk to the patient. 
Two-dimensional (2D) imaging, pulse wave and tissue 
Doppler velocities findings in ATTRwt-CA by Echo are 
similar to other forms of amyloidosis and other causes of 
HFpEF, like HTN, obesity, hypertrophic cardiomyopathy, 
Fabry’s disease and aortic stenosis. 
The most common 2D finding in cardiac amyloidosis is 
the presence of increased left ventricular thickness or LVH, 
however, unlike the other forms of HFpEF mentioned 
above, the LVH associated with cardiac amyloidosis is 
not due to cardiac myocyte hypertrophy but rather due to 
amyloid fibrils deposited in the extracellular matrix. The 
increase in LV wall thickness associated with ATTRwt-
CA is significantly greater than either AL (13) and 
ATTRm-CA (14). Another 2D finding that is associated 
with extracellular deposition of amyloid fibrils is a visually 
discernable “speckled” or granular “sparkling” texture 
appearance that seen by initial Echo machines, however, it is 
now less evident with modern echocardiographic machines 
due to almost exclusive use of harmonic frequency imaging. 
Diastolic dysfunction with preserved EF is a hallmark 
of cardiac amyloidosis by Echo. It is characterized by the 
evidence of grade I–II mitral valve inflow Doppler patterns 
with concomitant reduction of S’ and e’ tissue Doppler 
velocities at the basal septal and lateral walls and impaired 
systolic dysfunction assessed by myocardial strain (22,23) at 
the early stages of the disease. Forty percent of ATTRwt-CA 
of patients have moderate LV systolic dysfunction compared 
to 8–22% patients with ATTRm-CA and AL-CA (14). 
At the later stages, ATTRwt-CA patients develop severe 
diastolic dysfunction characterized by grade III mitral valve 
inflow pattern associated with very low S’/e’ velocities, and 
eventually reduction of EF (24). In fact, the development 
of systolic dysfunction may be present with preserved EF 
and predictive of poor outcomes in patients with cardiac 
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amyloidosis, measured by a reduction of myocardial 
contraction fraction (MCF), which is the calculated 
stroke volume divided by myocardial volume (25). Other 
non-specific findings with ATTRwt-CA are: (I) biatrial 
enlargement; (II) thickening of the mitral/aortic leaflets 
and intra-atrial septum; (III) small pericardial effusion; 
(IV) moderate pulmonary HTN; and (V) intracardiac 
thrombus (22,26). 
Advanced echocardiographic techniques, such as 
strain and strain rate imaging, have shown promise to 
help differentiate cardiac amyloidosis from hypertrophic 
cardiomyopathy or other causes of LVH. Strain and strain 
rate are echocardiographic techniques that use vendor 
specific proprietary software to track the longitudinal 
shortening of speckles within the 2D image of the left 
ventricular wall during systole and are quickly becoming 
clinically readily available. With all forms of cardiac 
amyloidosis, there is much greater restriction of basal 
speckle longitudinal movement compared to apical 
movement resulting in a relative ‘apical sparing’ pattern 
of longitudinal strain with bulls-eye plot (Figure 1) (27). 
Furthermore, Pagourelias et al. reported that EF global 
longitudinal strain ratio (EFSR), calculated by ratio of 
left ventricular EF and global longitudinal strain, had 
nearly 90% sensitivity and 92% specificity for all form of 
cardiac amyloidosis in the challenging subgroups with left 
ventricular wall thickness <16 mm with preserved EF (28). 
Cardiac biomarkers
Brain natriuretic peptide (BNP), N-terminal fragment 
of BNP (NT-proBNP) and cardiac troponins have been 
widely used to help with diagnosis, monitor treatment and 
prognostic evaluation both HFrEF and HFpEF. Elevation 
of NT-proBNP above >82 pg/mL has been shown to have 
sensitivity of 92% and specificity of 90% for presence of left 
ventricular abnormalities in patients with familial mutation 
in ATTR thus could be used as a potential screening test to 
initiate workup for ATTRm-CA (29). This observation may 
translate to patients with ATTRwt-CA in whom the log of 
BNP has been shown to have direct correlation with left 
ventricular thickness (30). Increasing serum levels of BNP, 
NT-proBNP and troponins were shown to have progressive 
correlation with disease severity and worse outcomes 
at increasing levels in patients with ATTRwt-CA (31). 
Furthermore, monitoring of these cardiac biomarkers 
is being employed to monitor treatment in ongoing 
clinical trials using disease modifying approaches for the 
treatment of ATTR cardiac amyloidosis (see “investigational 
medications” section later in the article).
Nuclear imaging
Nuclear imaging has emerged as  important non-
invasive tool in the diagnosis of suspected ATTR cardiac 
amyloidosis due to wide availability at a low cost, having 
few contraindications and the capacity to differentiate 
from other cardiomyopathies. Bone-avid tracers, like 
99mTc-DPD ( technet ium-3,3-diphosphono-1,2-
propanodicar-boxylic acid), 99mTc-PYP (technetium-
pyrophosphate)  and 99mTc-HMDP [technetium-
hydroxymethylene diphosphonate (Tc-HMDP)] have 
been shown to have high sensitivity and specificity for 
differentiating patients with ATTR CA, irrespective 
of genotype, from patients with AL-CA or others with 
HFpEF (32-37). The exact mechanism by which these 
radiotracers differentially accumulate in myocardium is 
not completely clear but may be due to differences in 
deposited amyloid proteins (38,39), higher calcium levels 
seen during the repair process (40) and/or higher degree 
of tissue microcalcifications in ATTR compared to AL 
cardiac amyloidosis (41). Irrespective of the mechanism, an 
international consensus document has confirmed that the 
combination of grade 2 or 3 cardiac uptake on a bone-avid 
tracer scan in the setting of absent monoclonal protein by 
serum immunofixation electrophoresis (IFE), urine IFE, 
and serum free light chain assay is diagnostic of ATTR 
cardiac amyloidosis as compared to AL-CA or other wall 
thickening diseases (42). Bokhari et al. (37) described 
a standardized imaging protocol using 99mTc-PYP to 
diagnose ATTR CA using Heart/Contralateral ratio ≥1.5. 
Nuclear imaging with 99mTc-DPD (43) and 99mTc-PYP (44) 
can diagnose the presence of cardiac involvement prior to 
any overt echocardiographic abnormalities and can predict 
major adverse cardiac events (34,35,39,43). Future studies 
are needed to establish the role of bone-avid nuclear tracers 
for the early identification of ATTRwt-CA, differentiating 
it from ATTRm-CA (confirmed by genetic testing) and 
evaluation of subsequent outcomes.
Scintigraphy imaging, which is inherently qualitative, 
falls short of being able to quantify the radioactivity at the 
affected sites thus cannot be used in assessing disease burden 
and response to therapy. Positron emission tomography 
(PET) is a nuclear modality that can circumvent this 
problem, emerging as a promising tool in the monitoring 
and management of cardiac amyloidosis. Recently discovered 
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amyloid binding PET tracers 18-F florbetapir (45,46) and 
11C-Pittsburgh compound B (PiB) (47,48) can identify both 
AL and ATTR cardiac amyloidosis. Case reports have shown 
cardiac uptake of another PET tracer [18F]-sodium fluoride 
only in patients with ATTRwt-CA and ATTRm-CA, 
but not in ones with AL-CA (49,50). 
Cardiovascular magnetic resonance
CMR is an important diagnostic and prognostic tool for 
cardiac amyloidosis. Various techniques utilizing different 
tissue imaging timing, with and/or without gadolinium 
contrast, and strain can provide detailed information about 
the presence, location, and distribution of hypertrophy, 
as well as cardiac function. One major drawback of using 
CMR is that gadolinium contrast is contraindicated in 
patients with moderate to severe kidney disease.
T1 sequence of  CMR, a composite measure of 
extracellular matrix and myocardial cells, with the use 
of gadolinium can help differentiate extracellular tissue 
thickening due to myocardial hypertrophy vs. extracellular 
deposition. Utilizing pre- and post-contrast T1 mapping, 
extracellular volume (ECV) can be calculated and is a 
direct measurement of the cardiac interstitium (51). ECV 
expansion can detect amyloid fibrils infiltration in AL and 
ATTR cardiac amyloidosis earlier than conventional testing 
and is quantitative marker of the amyloid burden lending 
itself with the potential use in early diagnosis and disease 
monitoring (52,53). Marked increased non-contrast T1 
relaxation times also seen in patients who have interstitial 
infiltration by amyloid fibrils and has good correlation with 
disease severity, future prognosis, and the potential to track 
changes over time (from natural progression or disease 
modifying therapy) (54-56). One of the major advantages 
of T1 mapping is that it does not require contrast which 
is contraindicated in advanced kidney disease, however, 
currently this technique has limited clinical availability 
due to technical challenges related to sequence- and 
vendor-specific differences (57,58). 
The myocardial deposition of amyloid fibrils in 
ATTR-CA increases ECV which serves as a reservoir 
for gadolinium accumulation leading to characteristic 
continuum of late gadolinium enhancement (LGE) (59). 
In the early stages of the disease there usually is no LGE 
enhancement that progresses to subendocardial and finally 
transmural (in non-ischemic pattern) LGE enhancement at 
the late stages (Figure 2), which also tracks with increasing 
ECV and a worse prognosis (58,60). In contrast, a diffuse-
subendocardial patterns is most commonly described in 
AL-CA disease (58,60), which has led to CMR based LGE 
scoring system that seems to differentiate between ATTR 
and AL cardiomyopathies (61). Future studies are necessary 
to establish similarities and differences between the LGE in 
patients with ATTRm-CA and ATTRwt-CA.
Traditional LGE imaging technique depends on 
normal myocardium to enhance the diseased area and has 
been limited in ATTR-CA due to difficult nulling, which 
have led to early and advanced disease misclassification. 
Phase-sensitive inversion recovery (PSIR) sequence that 
reduces the need for an optimal null point setting [initially 
described CMR evaluation of myocardial infarction (62)] 
makes LGE assessment in cardiac amyloidosis faster and 
operator-independent (58).
Feature tracking software applied to cine CMR datasets 
for assessment of left ventricular strain has shown good 
agreement between CMR and 2D Echo-derived myocardial 
longitudinal strain measurements (63) with apical sparing in 
longitudinal strain (64). 
Histopathological diagnosis
EMB with histopathology remains the gold standard for 
diagnosis of cardiac amyloidosis by showing deposition 
of amorphous deposits of amyloid fibrils in the heart. 
The binding of Congo red stain to the deposited amyloid 
fibrils leads to characteristic apple-green birefringence 
under polarized light microscopy (Figure 3) and an intense 
yellow-green fluorescence is seen when binding to thioflavin 
(image not shown). Precursor protein identification 
can be  accompl i shed by  immunohis tochemistry, 
electron microscopy, or mass spectrometry (preferred), 
depending upon institutional expertise. Fat pat biopsy 
with Congo red staining has sensitivity of 70–90% 
for diagnosis of systemic AL amyloidosis (65,66), 
but only 45% and 15% sensitivity for diagnosis of 
ATTRm-CA and ATTRwt-CA respect ive ly  (67) . 
Adjunctive laboratory tests to rule out AL include assaying 
for other organ dysfunction (e.g., proteinuria, alkaline 
phosphatase) and directly measuring the circulating light 
chains in plasma.
EMB is an invasive procedure that is associated with risks 
of complications including ventricular free-wall perforation 
of up to 0.4%, arrhythmia 0.5–1.0%, conduction 
abnormalities 0.2–0.4% (68) and requires expertise that is 
not readily available in many centers. With recent advance 
in Echo, CMR and nuclear imaging, multiple diagnostic 
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algorithms have been proposed for patients with suspected 
ATTRwt-CA (12,42,59,69,70).
Genetic testing
Once diagnosis of ATTR is confirmed via EMB with 
histology, it is important to offer DNA sequencing for the 
transthyretin gene (especially in clinical research studies) 
since the presence of a pathologic mutation can affect 
clinical trial options, predict sites of organ involvement, 
and have relevance for family members. The absence of 
amino acid sequence abnormalities by mass spectrometry is 
consistent with ATTRwt-CA, although mass spectrometry 
cannot detect all transthyretin mutations. 
Treatment
Limitations in treatment due to insufficient evidence-based 
approaches
While there are great advances in the treatment of AL 
amyloidosis by chemotherapy (71,72) and emerging new 
therapies for ATTRm-CA aimed at the reduction of mutant 
gene expression (73), TTR tetramer stabilization (74,75) 
and dissolution (76), currently there are no proven curative 
or disease modifying therapies for ATTRwt-CA. There 
are several possible reasons why ATTRwt-CA does not 
have any proven therapies: (I) it is a underrecognized and 
underdiagnosed leading to small patient cohorts to study 
and incomplete understanding of its natural history of 
the disease (13); (II) the disease presents late in life with 
multitude of age related comorbidities and mortality (13,14); 
and (III) the disease process is likely gradual thus curative 
or disease modifying therapeutic effects are difficult to 
measure (13). Consequently, most of the therapeutic 
considerations for ATTRwt-CA are based on expert opinion 
and observations from therapeutic effects on the other type 
of amyloidosis affecting the heart. 
Symptomatic relief and supportive care
The mainstay of therapy is supportive care aimed at 
symptomatic relief. The main symptoms of patients with 
ATTRwt-CA are congestion, fatigue, peripheral nerve 
pain, and hypotension. Relief of congestive symptoms 
and associated fatigue can be accomplished with the use 
of diuretics, including loop diuretics and thiazides in 
combination with mineralocorticoid receptor antagonist 
to help with potassium reabsorption. Diuretics should be 
used sparingly as these patients are preload dependent 
due to high filling pressures and can be used with 
weight-based parameters. Other medications typically 
used in cardiomyopathies, such as β-blockers, ACE-i 
and angiotensin receptor blockers (ARB), do not seem 
to modify the disease progression and often result in 
worsening fatigue and hypotension. B-blockers are usually 
not tolerated as they can reduce the inotropy of the heart 
resulting in decreased stroke volume and have a maladaptive 
blunting of chronotropy on which ATTRwt-CA patients 
relay for augmentation of their cardiac output. ACE-i and 
ARB medications often worsen hypotension in ATTRwt-
CA patients due pre-existing peripheral neuropathy 
affecting the autonomic nervous system of these patients. 
Hypotension can be managed with α-1 blocker midodrine 
and compression stockings. 
Atrial arrhythmias 
The symptoms associated with ATTRwt-CA are further 
exacerbated by atrial arrhythmias which are frequently 
associated with the condition (15). Rate control is difficult 
in these patients as β-blockers can worsen hypotension at 
higher doses, calcium channel blockers are contraindicated 
as they bind to the amyloid fibrils causing sustained 
worsening of CHF (77-79) and digoxin can cause cardiac 
toxicity due to progressive accumulation in the amyloid 
rich heart despite normal serum levels (80). Antiarrhythmic 
medications, such as amiodarone, can be used for rhythm 
control as patients are older and is overall well tolerated 
because it is usually not associated with deleterious 
hemodynamic changes. Symptomatic relief from atrial 
arrhythmias has been reported in a small cohort of 
ATTRwt-CA patients with catheter ablation (81). However, 
catheter ablation for atrial arrhythmias have high recurrence 
rate, necessitating AV ablation with permanent pacemaker 
placement in refractory cases.
Investigational medications
Currently there are no known curative or disease modifying 
agents for the treatment of ATTRwt-CA. However, 
there are several investigational medications that may 
have the potential to modify or even reverse the disease 
process. The strategies employed are ATTR disruption to 
reduced amyloid fibril aggregation, ATTR destabilization, 
and ATTR suppression. The combination of bile acid 
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tauroursodeoxycholic acid (TUDCA) and doxycycline 
have been shown to reduce ATTR aggregation in a mouse 
model of TTR V30M transgenic mouse model (82) as 
well as to be tolerated in a phase II clinical trial (75) and 
currently being evaluated [with un-reported results from a 
phase III clinical trial (clinicaltrials.gov; NCT01855360)]. 
Tafamidis meglumine, a ATTR destabilizing agent has been 
shown to reduce the progression of peripheral neuropathy 
in patients with TTR V30M TTRm-CM with ongoing 
clinical trials to evaluate its long-term cardiac effects in 
ATTRm as well as ATTRwt cardiomyopathies (clinicaltrials.
gov; NCT00935012 and NCT02791230). Patisiran is a 
siRNA, inhibiting ATTR mRNA translation, which has 
shown significant reduction of serum ATTR levels when 
administered intravenously in patients with familial amyloid 
polyneuropathy in a phase II clinical trial (83) with an 
ongoing long-term clinical trial in patients with familial 
ATTR (clinicaltrials.gov; NCT01960348).
Permanent pacemaker and defibrillator implantation 
Cardiac infiltration with amyloid fibrils can precipitate 
conduction system abnormalities, like bundle branch blocks 
and AV node dysfunction (84). A significant portion of 
patients with ATTRwt-CA have pacemakers at the time 
of diagnosis or have one implanted for high degree AV 
block (13). ACC/AHA guidelines suggest a case by case 
consideration for implantable cardioverter-defibrillator (ICD) 
implantation in patients for primary and secondary prevention 
due to limited clinical trials to show associated outcomes (85). 
Advanced therapies: left ventricular assist devices (LVAD) 
and heart transplantation
ATTRwt-CA patients have advanced heart failure 
symptoms and reduced life expectancy, findings which may 
qualify them to be considered for advanced heart failure 
options such as LVAD and/or heart transplantation. In a 
small single center report of 9 patients, LVAD implantation 
is technically feasible for ATTRwt-CA but it was associated 
with higher 24-month mortality and morbidity compared 
to other indications for LVAD implantation (86). A 
review of the Interagency Registry for Mechanically 
Assisted Circulatory Support (INTERMACS) database is 
necessary to be able to better evaluate outcomes of LVAD 
implantation for ATTRwt-CA. Patients with ATTRwt-
CA are usually not considered for heart transplantation 
due to their advanced disease presentation, age, and 
associated comorbidities. Indeed, in a literature review 
there was a single case report found of a 68-year-old patient 
who underwent heart transplantation for biopsy proven 
ATTRwt-CA who was reported to have a good 3-year 
outcome (87,88). 
Conclusions 
Cardiac amyloidosis is a group of diseases caused by 
extracellular deposition of misfolded proteins. ATTRwt-
CA is currently thought to have lowest prevalence among 
the different types of systemic amyloidosis, which is likely 
due to a low incidence from underdiagnosis, as it is found 
in 10–25% of all patients with HFpEF on autopsy studies. 
High clinical suspicion is necessary to initiate discussion 
with the affected patient about the risk, cost and benefit of 
early diagnosis and potential management, both of which 
often requiring a referral to a tertiary center. The total 
cost of testing, including EKG, Echo, CMR, and EMB is 
$5,000 to $15,000 (the variable cost to the patient) with the 
potential risks inherent to of each procedure. However, as 
in many rare or underdiagnosed conditions, an accurate 
diagnosis and appropriate level of follow up is needed to 
increase the patients able to participate in goal directed 
therapies and improve our understanding of the disease 
process as well as future possible treatments. Patients 
with signs and symptoms of heart failure (especially right 
sided symptoms), LVH out of proportion of duration and 
severity of HTN, arrhythmias, bundle branch blocks, have 
extracardiac manifestations of carpel tunnel syndrome and 
show intolerance to common cardiac medications should be 
evaluated for presence of ATTRwt-CA. Initial, diagnostic 
evaluation the highest sensitivity followed by ones with 
highest specificity should be performed to help diagnoses 
ATTRwt-CA: (I) Echo strain patterns with characteristic 
apical sparing and reduction of ratio of stroke volume 
to myocardial volume; (II) quantitative and qualitative 
characterization by nuclear scintigraphy; and (III) CMR 
tissue characterization with LGE, ECV and T1 mapping. 
Only if those non-invasive modalities are highly suggestive 
of ATTRwt-CA, EMB, followed by genetic testing should 
be performed as the diagnostic gold standard as it is not 
readily available and is invasive. Once patients are diagnosed 
to have ATTRwt-CA clinical consideration should be taken 
to adjust their medical therapy to best support their unique 
pathophysiology and patients should be considered to 
participate in the ongoing or upcoming clinical trials testing 
possible novel disease modifying therapies. 
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